Introduction
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) are lymphoid malignancies representing a heterogeneous group of diseases that vary with respect to morphological, cytogenetic and immunologic features of the T-lymphoblasts. 1 The discovery of chromosomal rearrangements in these disorders has been pivotal in the identification of the genes involved in T-ALL development and normal thymocyte differentiation. 2, 3 In most instances, these chromosomal aberrations are translocations that preferentially involve the T-cell receptor TCRad locus (14q11) and to a much lesser extent the TCRb locus (7q34) and affect a wide array of genes with oncogenic properties 1p32(TAL1), 1p34(LCK), 8q24(MYC), 9q34(TAL2), 9q34(TAN1/NOTCH1), 10q24 (HOX11), 11p13 (RBTN2/LMO2), 11p15(RBTN1/LMO1), 14q32(TCL1), 19p13 (LYL1), 21q22(BHLHB1) and Xq28 (MTCP1). [3] [4] [5] [6] Translocations affecting TCR genes largely result in deregulated expression of proto-oncogenes by juxtaposing promoter and enhancer elements of TCR genes in the proximity of these developmentally important genes. 7 Interestingly, further molecular studies revealed that some of these genes (TAL1, HOX11, NOTCH1) were functionally activated in a much higher frequency than expected from a cytogenetic point of view, [8] [9] [10] further underlining the importance of the original cytogenetic investigations. Also, biallelic expression has been reported in about half of the cases with TAL1, LMO2 and HOX11 expression pointing at disturbance of an upstream regulatory control mechanism. 11 In contrast to B-ALL, in which predominantly chimeric transcription factor proteins are generated, gene fusions occur in a much lower rate in T-ALL (predominantly MLL/ENL and CALM/AF10). [12] [13] [14] Recently, the spectrum of chromosomal abnormalities in T-ALL has been further widened by the finding of new recurrent but cryptic alterations. First, a cytogenetically undetectable translocation t(5;14)(q35;q32) was found in about 20% of childhood T-ALL juxtaposing the HOX11L2 gene (5q35) to the distal region of the BCL11B gene. 5 A further remarkable finding was the extrachromosomal (episomal) amplification of NUP214-ABL1 fusion genes in 6% of T-ALL cases leading to constitutively phosphorylated tyrosine kinase activity, which can be inhibited upon addition of imatinib, a selective inhibitor of ABL1 kinase activity. 10, 15, 16 Recently, we observed yet another recurrent chromosomal rearrangement, that is, an inv(7)(p15q34) in a subset of T-ALLs. This rearrangement juxtaposes the distal part of the HOXA gene cluster on 7p15 to the TCRb locus on 7q34 and causes increased HOXA10 and HOXA11 expression levels. 17 The occurrence of this inv(7) as well as a t(7;7)(p15;q34) was subsequently also demonstrated by Soulier et al. 18 Interestingly, upregulated HOXA gene expression was also found in MLL-ENL and CALM-AF10-positive T-ALLs, thus pointing at a more general role of HOXA genes in T-cell oncogenesis. 19, 20 These observations thus indicate that a plethora of genes can be implicated in the development of T-ALL as a result of various recurrent chromosomal changes, many of which remained undetected upon cytogenetic investigation until recently. In particular, the finding of a cryptic t(7;11)-(q34;q24) involving the TCRb locus (7q34) in a childhood T-ALL case 21 and the new recurrent inv(7)(p15q34) triggered the screening for additional cryptic TCR rearrangements in a cohort of 126 T-ALL patients and 19 T-ALL cell lines. Our findings show that the majority of TCRb chromosomal rearrangements remained undetected upon routine karyotyping and that new T-cell oncogenes may be implicated in some of these cases (Figure 1 ).
Materials and methods

Patients and controls
Cytogenetic cell suspensions or unstained slides from 126 diagnostic T-ALL (n ¼ 109) and T-LL (n ¼ 17) samples were collected retrospectively from cytogenetic centers between 1988 and 2005. Diagnosis of T-ALL/LL was made according to the morphological and cytochemical criteria of the FrenchAmerican-British classification 22 and by imunophenotyping. The selection of cases was based on the availability of fixed cell suspension or unstained slides, which permit fluorescent in situ hybridization (FISH) investigation. Molecular data and immunophenotype were available only for most recent cases and are not shown. This cohort of T-ALL and T-LL cases included 80 children and 46 adults. The 19 T-ALL cell lines were purchased from DSMZ (http:// www.dsmz.de, Braunschweig, Germany). Peripheral blood lymphocytes from healthy donors with normal karyotypes served as negative controls for validation and cutoff level determination of the different FISH assays. Cell suspensions from T-ALL cases or cell lines with cytogenetically proven breakpoints at the different known T-cell oncogenes (LCK, MYC, HOX11, LMO2, LMO1, NOTCH1) were used as positive controls.
Methods
Cytogenetic analysis. Diagnostic specimens (bone marrow, blood and pleural fluid) and cell lines were cultured and harvested for cytogenetic analysis according to established methods. Chromosome slides were G or R banded. Chromosome aberrations are described according to guidelines of an International System for Human Cytogenetic Nomenclature (ISCN 1995). 23 Clone selection and validation. RPCI-11 (Human BAC Library) clones were selected using the bioinformatics resources available at National Center for Biological Information (http:// genome.ucsc.edu) and Ensembl Genome Browser (http:// www.ensembl.org/). Clones were provided by the Welcome Trust Sanger Institute (Cambridge, UK) and Invitrogen (Paisley, Scotland).
Disruption of the TCR loci was assessed by dual color FISH with TCR flanking probes. Clones for the TCRad, TCRb and TCRg applied in the present study are listed in Table 1 . Additional FISH probes used to confirm the involvement of TCR partner genes in cases carrying TCRb and/or TCRad chromosomal rearrangement (identified by a split signal of the flanking probes) are listed in Table 1 , with the exception of MYC for which we applied the LSI MYC Dual Color, Break Apart Rearrangement Probe (Vysis, Abbott, Ottignies, Belgium). DNA isolation of bacterial artificial chromosome (BAC) clones and FISH was performed as described previously. 24 Subsequently, large-scale DNA amplification was performed using the GenomiPhi Amplification Kit (Amersham Biosciences, Roosendaal, The Netherlands), which utilizes bacteriophage Phi-29DNA polymerase and exponentially amplifies single-or double-stranded linear DNA templates during an isothermal (301C), strand displacement reaction. 25 Phi-amplified DNA was labeled as described previously 24 using spectrum green-and spectrum orange-dUTP (SG-dUTP and SO-dUTP, Vysis, Abbott).
Validation of BAC clone genomic positions of TCRad, TCRb and TCRg flanking clones was performed using STS (sequence tagged site) PCR with two STS genomic markers per BAC clone.
Using this approach, the genomic positions of the different TCR gene loci provided by the bioinformatics resources were confirmed.
Determination of cutoff levels. Determination of cutoff levels of these new probe sets was performed by counting 200 nuclei in five negative controls (peripheral blood lymphocytes from healthy donors) for each probe set.
Based on the results in negative controls, a split was defined as a spatial separation of the flanking probes of more than three times the estimated signal diameter. 26 Using these criteria, the cutoff levels of the different probe combinations were 6% for TCRad, 6.5% for TCRb and 2% for TCRg.
Results
A total of 126 T-ALL/LL cases and 19 T-ALL cell lines were investigated. Karyotypic analysis was successful in 119 cases, Table 1 Flanking bacterial artificial chromosomes clones used for FISH analysis in the present study
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Abbreviations: FISH, fluorescent in situ hybridization; TCR, T-cell receptor. (Table 2) , whereas translocations affecting the 7q34 locus were detected in only four of 24 cases. Partial deletions of chromosome 7q or 7p were detected in three cases and two cases showed additional material on 7q. Taken together, TCRb genomic rearrangement was unsuspected from cytogenetic analysis in as much as 14 of 24 (58.3%) cases when excluding failures. Two out of 19 cell lines screened with the TCRb flanking probes showed genomic rearrangement of this locus with LCK (T-ALL cell line HSB2) and NOTCH1 (T-ALL cell line SUP-TI) as partner genes (Table 2) .
Molecular cytogenetic study of T-ALL
Translocations affecting the TCRad locus in T-cell acute lymphoblastic leukemia
Translocations involving the TCRad locus were detected in approximately the same number of patients as for TCRb, that is, 22/126 (17.4%) cases (Tables 2 and 4 ) and mostly included T-ALL (n ¼ 21). However, involvement of known T-cell oncogenes was confirmed in only 12 of 22 rearranged cases. Unexpectedly, one TCRad rearranged case (no. 23) showed a balanced rearrangement with the TCRb locus, which brings the total number of identified TCRad partner genes to 13 out of 22. These findings suggest that many of these rearrangements targeted unknown T-cell oncogenes. Within the TCRad rearranged group involving known T-cell oncogenes, HOX11 was most frequently involved followed by LMO2, TAL1 and MYC, which involved two cases each. TCL1, HOXA and TCRb were detected in single cases. For the remaining nine cases carrying a TCRad rearrangement, partner genes could not be identified. Interestingly, TCRad rearrangements showed involvement of an unknown partner gene on chromosome 6q22 (case no. 40) and 20p12 (case no. 41) ( Table 2) . Of the 19 cell lines screened with TCRad flanking clones, five showed rearrangements with partner genes LMO1 (RPMI 8402), LMO2 (TALL 104), MYC (MOLT16 and KE-37), HOX11 (ALL-SIL) and an unidentified gene (SUP-TI). In contrast to TCRb rearrangements, TCRad rearrangements were more frequent in children (16/80; 20%) versus adult T-ALL patients (6/46: 13%).
In this group of TCRad rearranged cases (n ¼ 22), abnormal karyotypes were present in 19 patients ( Table 2 ). Of these, translocations involving the TCRad locus were obvious from banding analysis in only 12 of these 19 patients. In seven cases with clonal karyotypes, no 14q11 rearrangement was apparent, indicating that at least 30% (7/22) of TCRad-positive cases in this series was cryptic. This could be explained in one of these cases through the presence of complex abnormalities. This case (no. 28) showed two subclones carrying rearrangement of chromosome 14 at different chromosome bands. One subclone carried a rearrangement of chromosome 14 at the B14q32 band (IgH locus) and was translocated to the long arm of chromosome 20, 24 revealing a t(14;20)(q32;q12). In another subclone, chromosome 14 showed disruption of the TCRad locus (14q11) with inversion of the distal probe to the short arm of chromosome 14 thus revealing a new inv(14)(p?q11).
Simultaneous occurrence of TCRb and TCRad genomic rearrangements
Five T-ALL patients (cases nos. 1, 6, 10, 13, 23) and one T-ALL cell line (SUP-TI) carried genomic rearrangements of both TCRb and TCRad loci. In four of these patients, both TCR genes targeted different T-cell oncogenes (Table 2) as confirmed by FISH with the appropriate probes. Unexpectedly, patient nos. 13 and 23 showed a rearrangement between the TCRb and TCRad gene loci, unbalanced in case no. 13 and balanced in patient no. 23. Five of these patients were children, possibly reflecting the higher susceptibility to genomic rearrangements involving TCR loci during childhood.
Previously unreported chromosome aberrations in T-cell acute lymphoblastic leukemia
Chromosome aberrations found in this series, which have not been reported previously in T-ALL, are listed in Table 3 . Fluorescent in situ hybridization investigation for oncogenes known to be involved in leukemogenesis (LMO1, LMO2, HOX11, HOXA, ETV6, NUP98) were applied and in most cases turned out to be negative, indicating that a large set of putative T-cell oncogenes still remains undiscovered.
Discussion
Here we report the results of a comprehensive FISH screening performed in 109 T-ALL, 17 T-LL and 19 T-ALL cell lines using TCR flanking FISH probes to determine the incidence of chromosomal rearrangements involving the TCR genomic loci TCRad (14q11), TCRb (7q34) and TCRg (7p15). This approach allowed us to demonstrate for the first time that TCRb rearrangements occur in a similarly high frequency as TCRad Molecular cytogenetic study of T-ALL B Cauwelier et al Table 2 Biological characteristics and cytogenetic findings of TCRb-and/or TCRad-positive T-ALL patients and cell lines with identified partner gene and revised abnormal karyotypes ;q26) , À4, À5, t(6;14)(q22;q11), À8, del(10)(q23q25), t(10;11)(q23;q14), der(12)(t(5;12)(q22;p12), der(12)(t(8;12)(q21;q24), ins(13;?), add(15)(p13), +3 mar1, +mar2 [6] /46,XX [2] Unknown (6q22?) Negative 47,XX,t(3;6)(q23;q26), À4, À5, t(6;14)(q22;q11), -8, del(10)(q23q25), t(10;11)(q23;q14), der(12)(t(5;12)(q22;p12), der(12)(t(8;12)(q21;q24), ins(13;?), add(15)(p13), +3 mar1, + mar2 41 15 F 92,XXXX, del (6)(q14q16), del(9)(p11), t(14;20)(q11;p12) [17] /46,XY [7] Unknown (20p12 ?) Negative 92,XXXX, del (6)(q14q16), del(9)(p11), t(14;20)(q11;p12)
T-ALL cell lines RPMI 8402 79-91, XXX, ÀX, der(1)t(1;9)(p35;q11),+3, +3, dup(4)(q13q23)x2, del(6)(q14q22)x2, À10, t(11;14)(p15;q11)x2, À13, add(13)(q34), À14, +15, add(15)(p13), À18, À20, +mar1, +mar2
LMO1(11p15)
Negative 79-91, XXX, -X, der(1)t(1;9)(p35/36;q11),+3, +3, dup(4)(q13q23)x2, del(6)(q14q22)x2, À10, t(11;14)(p15;q11)x2, À13, add(13)(q34), À14, +15, add(15)(p13), À18, À20, +mar1, +mar2 ALL-SIL 90-95, XX/XXYY, t(1;13)(p32;q32)x2, +6, del(6)(q25)x2, +8, +8, del(9)(?p23p24)x2, t(10;14)(q24;q11.2)x2, add(17)(p11)x2
HOX11 (10q24) Negative 90-95, XX/XXYY, t(1;13)(p32;q32)x2, +6, del(6)(q25)x2, +8, +8, del(9)(?p23p24)x2, t(10;14)(q24;q11.2)x2, add(17)(p11)x2 TALL-104 46,XY,t(11;14)(p13;q11) LMO2 (11p13) Negative 46,XY,t(11;14)(p13;q11) HSB2 42-46, XY, t(1;7)(p34;q34) Negative LCK (1p34) 4 2 B46, XY, t(1;7)(p34;q34) KE-37 86-92, XXYY, t(7;12)(q32-33;p12-13)x2, +8, der(8)t(8;14)(q24;q11)x4, À14, À14, der(14)t(8;14)(q24;q11)x2
MYC (8q24) Negative 86-92, XXYY, t(7;12)(q32-33;p12-13)x2, +8, der(8)t(8;14)(q24;q11)x4, À14, À14, der(14)t(8;14)(q24;q11)x2 MOLT-16 43-47,XX, t(3;11)(p21;p13), t(8;14)(q24;q11) MYC (8q24) Negative 43-47,XX, t(3;11)(p21;p13), t(8;14)(q24;q11) SUP-TI 85, XXX/XXX?Y, inv(2)(p22q11)x2, t(2;?20)(p13;?p11), del(4)(q31q35), del(6)(q25)x2, add(7)(q32), À8, À8, -9, add(9)(q34)x2, inv(14)(q11q32)x2, À12 Unknown NOTCH1 (9q34) 85, XXX/XXX?Y, inv(2)(p22q11)x2, t(2;?20)(p13;?p11), del(4)(q31q35), del(6)(q25)x2, t(7;9)(q34;q34), À8, À8, À9, inv(14)(q11q32)x2, À12
rearrangements, that is, in 19% of T-ALL patients. Of further importance, we showed that as much as half (14/24) of the TCRb and about one-third (8/22) of the TCRad rearrangements were not detected upon karyotypic analysis. Our study thus indicates that using standard karyotyping, chromosomal rearrangements involving T-cell receptors (in particular TCRb) have been significantly underestimated so far. 27 In line with previous reports, no TCRg aberrations were observed in this series. Apparently, these TCRg rearrangements are confined to T-cell tumors in patients with ataxia telangiectasia (ATM) where these rearrangements are frequently found. 28 The frequency and age distribution of TCRad rearrangements in our study are in line with the series reported by Heerema et al., 29 whereas other larger studies of adult T-ALL found that the frequency of TCRad rearrangements was much higher in adults compared to childhood T-ALL. 30, 31 For patients showing a TCRb locus rearrangement, conventional karyotyping showed aberrations in only 3.1%, which is somewhat in between previous cytogenetic reports of 7q34 abnormalities in adult (7.5%) 27 and childhood (1%) 30 T-ALL. The incidence of TCR rearrangements (TCRb and/or TCRad) was slightly higher in the T-ALL group, which was possibly biased by the much larger number of patients with T-ALL compared to T-LL. In the T-LL subgroup, 4/17 (23.5%) were positive for a TCR rearrangement, whereas 36/109 (33%) T-ALL showed one of these rearrangements.
The high incidence of cytogenetically undetected TCRb (14 out of 24 TCRb-positive cases) and TCRad (eight out of 22 TCRad-positive cases) rearrangements is remarkable. For TCRb rearrangements, eight of 14 cytogenetically undetected cases showed other clonal rearrangements and re-evaluation of the karyotypes allowed us to detect the TCRb aberration in two cases (nos. 3 and 4). This could be explained by the distal localization of the TCRb locus (7q34) together with a distal chromosomal position of the breakpoints of the TCRb partner genes, that is, t(7;11)(q34;q24), t(7;10)(q34;q24) and inv(7)(p15q34). In two cases (nos. 7 and 8) only normal metaphases were found at diagnosis and re-evaluation of karyotypes did not show the aberration, suggesting that only non-leukemic cells were cultured. This explanation is not valid for the TCRad locus rearrangements, which should be readily detectable on G-banding analysis. For TCRad rearrangements that remained undetected upon karyotyping, two were presented as a marker chromosome (case nos. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , one resulted form a complex rearrangement (case no. 28) and a third (case no. 26) was not detected as probably only normal cells were karyotyped. Re-evaluation of case no. 26 remained negative. Interestingly, for the remaining TCRad-positive cases that remained undetected, chromosomal rearrangements were found in karyotypically abnormal cells (case nos. 32, 33, 35, 37) raising the question that these represent true cryptic rearrangements.
Preferential partner genes for TCRb in our series include HOXA (7p15) 17 and HOX11 (10q24), which were involved in seven and four cases, respectively. Recently, HOXA cluster genes were shown to be involved in a chromosomal rearrangement with the TCRad (14q11) locus in a T-ALL patient (case no. 30) carrying a t(7;14)(p15;q11) (unpublished observation).
The finding that in 14 TCRad or TCRb chromosomal rearrangements the partner gene could not be identified after testing of all genes known to be implicated in T-ALL is of great potential importance. Also, two new translocations involving the TCRad locus were found in this series, that is, t(6;14)(q22;q11) (case no. 40) and t(14;20)(q11;p12) (case no. 41) ( Table 2) . Further efforts to identify these putative new partner genes are ongoing. Recently, a new translocation, that is, t(7;11)(q34;q24) 21 affecting the TCRb locus and an as yet unidentified partner gene on chromosome 11q24 was described (case no. 1 in Table 3 ) and is analyzed further. Other chromosomal aberrations not reported previously in T-ALL (Table 2 ) include three cases with rearrangements of chromosome 9p21-24. This is the region harboring the CDKN2A (encoding p14 and p16 proteins) and CDKN2B (encoding p15 protein) tumor suppressor genes, which are the primary targets of 9p21 deletions in T-ALL and have been described to be present in 65% of T-ALLs. 32, 33 Translocations affecting this gene locus have been reported in ALL but mostly in B-ALL. 30, 34, 35 Interestingly, two of these patients carrying a rearrangement of 9p also showed a homozygous deletion of p16.
An interesting observation is the presence of rearrangements of both TCRad and TCRb loci in six patients and one cell line. Five of these patients were children, possibly reflecting the higher susceptibility for errors in VDJ recombination as a consequence of greater antigen exposure during childhood. In four patients, involvement of different T-cell oncogenes by both TCRb and TCRad genes was confirmed using FISH with the appropriate flanking BAC clones. No preferential involvement of a particular gene seems evident from this small series, but it should be noted that four of the 12 partner genes in these cases remained unidentified. Interestingly, two patients (case nos. 13 and 23) carried a translocation between the two TCR loci: TCRb (7q34) and TCRad (14q11); unbalanced in case no. 13 and balanced in case no. 23 . So far, rearrangements between two Table 3 Chromosome aberrations not previously reported in T-ALL t(X;10)(p23;q23) t(1;9)(p13;p21) inv(3)(p11q22) t(3;6)(q23;q26) t(3;11)(p12;p15) t(4;9)(q25;p21) t(5;7)(p15;q31) t(6;10)(q25;q24) t(6;14)(q22;q11) t(6;16)(p21;p12) t(6;16)(q21;q23) t(6;17)(p21;p13) t(7;9)(p11;p24) t(7;12)(p14;p13) t(7;14)(p12;q24) t(8;10)(q21;q21) t(9;20)(p21;q12) t(10;12)(p12;q21) inv(11)(p12q23) t(11;12)(q13;p13) t(11;12)(q23;p13) Dic(14;19)(p11;p11) t(14;20)(q32;q12)
Abbreviation: T-ALL, T-cell acute lymphoblastic leukemia.
Table 4
Frequency of detected TCR chromosomal rearrangement using conventional karyotyping versus FISH In percentage of T-ALL abnormal karyotypes.
Molecular cytogenetic study of T-ALL B Cauwelier et al TCR loci, TCRg (7p15) and TCRad (14q11), have been reported in a high frequency in patients with ATM. 28 However, this aberration has also been found at very low frequencies in T-lymphocytes from healthy individuals. 36 These observations raise the possibility that rearrangements affecting both TCR loci are not merely chromosomal aberrations associated with tumorigenesis, but could represent the capacity of the recombinase system to generate additional immune diversity. 37 In the light of the present findings, we would recommend thorough cytogenetic and molecular cytogenetic screening for cases included in ongoing and future gene expression profiling studies in T-ALL. This information may be critically important in the data analysis and delineation of genetic subgroups. Also, it will broaden our understanding of the various genetic mechanisms that lead to unscheduled activation or sustained expression of the plethora of genes implicated in T-cell oncogenesis.
